) (A) Ras activation induces downstream ERK phosphorylation. Western blot showing phospho-ERK and ERK 1/2 protein levels in MCF10A ER-hRas V12 cells lysed before 4-OHT addition and after 1, 5 and 10 hours treatment. Graph shows mean phospho-ERK/total ERK ratio quantified from 3 independent blots. (B) Ras V12 alters cell shape in metaphase but not interphase. Box plots showing cell length and aspect ratios in interphase and metaphase for the conditions shown in Figure 1C . (C) Ras V12 activation alters metaphase cell area. Box plot showing metaphase area for MCF10A and MCF10A ER-hRas V12 with 5 -15 hours of ethanol (-) or 4-OH-tamoxifen (+) treatment and for constitutive MCF10A+hRas v12 cells. Cells were imaged every 5 minutes for 15 hours using phase contrast microscopy and the shapes recorded for every metaphase (5 minutes before anaphase elongation or furrowing). (D) The effect of Ras V12 activation depends on cell confluence. Box plot showing metaphase length for MCF10A ER-hRas V12 cells following 5 -15 hours ethanol or 4-OH-tamoxifen treatment comparing cells plated in sparse (defined as single cells or cells with <2 neighbours) or confluent (cells surrounded by other cells on all sides) conditions.
Supplementary
) (A-C) MEK and ERK inhibition alters mitotic shape in normal MCF10A cells, constitutive Rasexpressing cells and h-Ras transformed MCF10A-CA1 cells. Plot of metaphase length for MCF10A cells (A) constitutive MCF10A+hRas v12 cells (B) and MCF10A-CA1 cells (C) following up to 15 hours treatment with DMSO or 2 µM PD 184352, 10 µM Selumetinib or 10 µM GDC-0994. Measurements were taken from time-lapse brightfield images at the frame (5 mins) before anaphase. (D) kRas V12 affects metaphase shape in a similar way to hRas V12 . Box plot of metaphase cell length (Feret) for MCF10A ER-kRas V12 with 5 -15 hours of ethanol or 4-OH-tamoxifen treatment.
(E-G) MEK and ERK inhibition alters mitotic shape in a kRas-transformed cancer cell line. Western blot showing ERK and RSK phosphorylation in Capan-1 cells following 5 hours of treatment with 2 µM PD 184352, 10 µM Selumetinib or 10 µM GDC-0994 (E). Representative brightfield images (F) and quantification of metaphase length (G) in Capan-1 cells following 5-15 hours treatment with the same inhibitors. Measurements are taken from time-lapse brightfield images at the frame (5 mins) before anaphase. Scale bars are 10 µm. 
